The NYU Langone-Sage NDHCC will expand upon the work Sage Bionetworks has been doing for more than a decade, building infrastructure that makes collaborative biomedical research possible at scale.” — ...
– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results